2022 ASCO Annual Meeting*

Download All
June 3-7, 2022; Chicago, Illinois
Review slidesets and expert analyses of key data from the 2022 Clinical Oncology Annual Scientific Meeting!

Breast Cancer and Gynecologic Cancers

Capsule Summary Slidesets

Results from the randomized phase II FAKTION trial showed that the addition of capivasertib to fulvestrant prolongs survival in ER+/HER2- advanced breast cancer and suggest that capivasertib primarily benefits patients with PI3K/AKT/PTEN pathway alterations.

Released: June 9, 2022

Compared with placebo, pembrolizumab added to neoadjuvant chemotherapy was associated with lower residual cancer burden in patients with TNBC and with prolonged EFS even in patients without a pCR.

Released: June 14, 2022

Pembrolizumab + chemotherapy ± bevacizumab prolonged PFS and OS vs placebo + chemotherapy ± bevacizumab in key patient populations, including those defined by bevacizumab use, histology, platinum use, and prior chemoradiotherapy.

Released: June 9, 2022

Tisotumab vedotin plus pembrolizumab demonstrated promising, durable antitumor activity with a tolerable safety profile in recurrent or metastatic cervical cancer.

Released: June 9, 2022

Dostarlimab was associated with overall response rates of 45.4% and 15.4%, including durable responses, in dMMR/MSI-H and pMMR/MSS advanced/recurrent endometrial cancer.

Released: June 10, 2022

In the ORZORA trial, maintenance olaparib showed similar OS outcomes in patients with platinum-sensitive relapsed ovarian cancer regardless of whether patients had a germline or a somatic BRCA mutation or a non-BRCA HRR mutation.

Released: June 13, 2022

Addition of the GR modulator relacorilant to nab-paclitaxel numerically improved OS vs nab-paclitaxel alone in patients with recurrent platinum-resistant ovarian cancer.

Released: June 15, 2022

First interim analysis finds that sacituzumab govitecan extends progression-free survival in patients with heavily pretreated metastatic HR-positive/HER2-negative breast cancer.

Released: June 8, 2022

Final results showed no significant difference in overall survival with the addition of palbociclib to frontline letrozole in postmenopausal patients with ER-positive/HER2-negative breast cancer.

Released: June 10, 2022

Ribociclib combined with switching endocrine therapy improved PFS in patients with HR-positive/HER2-negative metastatic breast cancer who progressed on prior standard of care CDK4/6 inhibition with endocrine therapy.

Released: June 9, 2022

Trastuzumab deruxtecan improves survival in patients with HER2 IHC1+ and IHC2+/ISH-negative advanced breast cancer.

Released: June 8, 2022

Women with clinically favorable low-risk breast cancer demonstrated a 5-year rate of local recurrence of less than 5% after breast-conserving survey and endocrine therapy without radiotherapy.

Released: June 15, 2022

First-line maintenance therapy with rucaparib significantly improved PFS vs placebo regardless of HRD status in patients with advanced ovarian cancer.

Released: June 14, 2022

In MITO23, trabectedin failed to improve survival compared with investigator’s choice of single-agent chemotherapy in patients with BRCA-mutant or BRCAness phenotype recurrent ovarian cancer.

Released: June 17, 2022
Provided by Clinical Care Options, LLC

Contact Clinical Care Options

For customer support please email: customersupport@cealliance.com

Mailing Address
Clinical Care Options, LLC
12001 Sunrise Valley Drive
Suite 300
Reston, VA 20191

Supported by educational grants from
AstraZeneca
Daiichi Sankyo, Inc.
Gilead Sciences, Inc.
GlaxoSmithKline
Merck Sharp & Dohme Corp.
Seattle Genetics

Leaving the CCO site

You are now leaving the CCO site. The new destination site may have different terms of use and privacy policy.

Continue

Cookie Settings